HR
HRMY.US Harmony Biosciences Holdings
- Market cap
- USD 1.98B
- P/E
- 11.2x
- P/B
- 1.85x
- ROE
- 19.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HRMY.US undervalued?
Graham numberHRMY.US trades 4.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harmony Biosciences Holdings fundamental analysis
No fundamental analysis for Harmony Biosciences Holdings yet.
Harmony Biosciences Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); i…
Full company profileHarmony Biosciences Holdings financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harmony Biosciences Holdings annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 6.00M | 160M | 305M | 438M | 582M | 715M | 868M | 994M |
| Gross Profit | -184K | 4.42M | 132M | 250M | 354M | 461M | 558M | 670M | 743M |
| Operating Income | -41.4M | -146M | 17.0M | 87.5M | 120M | 192M | 191M | 208M | 241M |
| EBITDA | -41.3M | -143M | 1.51M | 80.5M | 147M | 222M | 233M | 255M | 293M |
| Net Income | -39.9M | -152M | -36.9M | 34.6M | 181M | 129M | 145M | 159M | 208M |
| EPS | -0.81 | -2.39 | -0.64 | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 | 3.49 |
| Balance Sheet | |||||||||
| Total Assets | 89.3M | 107M | 427M | 433M | 674M | 811M | 999M | 1.27B | 1.48B |
| Total Liabilities | 7.75M | 118M | 330M | 247M | 271M | 344M | 340M | 401M | 406M |
| Shareholders' Equity | 81.5M | -11.6M | 97.2M | 187M | 403M | 467M | 659M | 870M | 1.07B |
| Cash & Short-term Investments | 83.5M | 24.5M | 229M | 234M | 323M | 353M | 467M | 775M | 771M |
| Total Debt | 324M | 97.9M | 194M | 196M | 192M | 194M | 181M | 240M | 149M |
| Cash Flow | |||||||||
| Operating Cash Flow | -38.8M | -75.4M | -2.99M | 98.6M | 144M | 219M | 220M | 348M | 263M |
| Capital Expenditure | 1.34M | 149K | 2.00M | 298K | 172K | 312K | 1.15M | 310K | 0.00 |
| Free Cash Flow | -40.1M | -75.6M | -4.99M | 98.3M | 144M | 219M | 219M | 348M | 263M |
| Ratios | |||||||||
| ROE | -48.9% | - | -38.0% | 18.5% | 45.0% | 27.6% | 22.1% | 18.2% | 19.4% |
| ROA | -44.7% | -142.4% | -8.7% | 8.0% | 26.9% | 15.9% | 14.6% | 12.5% | 14.1% |
| Net Profit Margin | - | -2,535.1% | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% | 20.9% |
| Debt to Equity | 3.98x | - | 2.00x | 1.05x | 0.48x | 0.41x | 0.28x | 0.28x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Harmony Biosciences Holdings dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 5.06M | 0.08 | 3.9% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 200M | 3.46 | - |
| 2019 | USD 144M | 2.26 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Harmony Biosciences Holdings
- Insiders 2.11%
- Institutions 97.89%
- Public & others 0.00%
- Shares outstanding 58.7M
- Free float 52.6M
Top funds holding HRMY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.98M | 5.07% | -0.16% | Oct 2026 |
| Avantis US Small Cap Value ETF | 2.83M | 4.82% | +0.52% | Oct 2026 |
| HBM Healthcare Investments AG Ord | 2.15M | 3.66% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.56M | 2.66% | +0.35% | Sep 2026 |
| iShares Russell 2000 ETF | 1.15M | 1.95% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.11M | 1.90% | -1.42% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 933K | 1.59% | +0.27% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 621K | 1.06% | -4.28% | Sep 2026 |
| Handelsbanken SC Global (A15 SEK) | 553K | 0.94% | +320.32% | Oct 2026 |
| DFA U.S. Small Cap Value I | 530K | 0.90% | +37.26% | Sep 2026 |
| Fidelity Growth Company Fund | 525K | 0.89% | -12.50% | Aug 2026 |
| Fidelity Small Cap Index | 495K | 0.84% | +0.16% | Aug 2026 |
| Invesco Pharmaceuticals ETF | 453K | 0.77% | +0.45% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 449K | 0.77% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 447K | 0.76% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 423K | 0.72% | -0.38% | Oct 2026 |
| DFA U.S. Targeted Value I | 383K | 0.65% | +3.59% | Sep 2026 |
| Dimensional US Targeted Value ETF | 291K | 0.50% | +0.03% | Oct 2026 |
| Bridge Builder Mid Cap Fund | 289K | 0.49% | +86.19% | Oct 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 280K | 0.48% | 0.00% | Oct 2026 |
Top institutions holding HRMY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 7.10M | 12.09% | +0.45% | Jun 2026 |
| FMR Inc | 3.57M | 6.09% | +13.19% | Jun 2026 |
| American Century Companies Inc | 3.11M | 5.30% | +22.60% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 2.88M | 4.91% | +6.12% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.65M | 4.51% | +10.71% | Sep 2026 |
| LSV Asset Management | 2.21M | 3.76% | +6.98% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.11M | 3.58% | +0.13% | Jun 2026 |
| State Street Corp | 1.86M | 3.17% | +4.20% | Jun 2026 |
| Armistice Capital, LLC | 1.56M | 2.66% | -3.69% | Jun 2026 |
| Geode Capital Management, LLC | 1.44M | 2.46% | +9.07% | Jun 2026 |
| Renaissance Technologies Corp | 1.40M | 2.38% | +16.92% | Sep 2026 |
| Arrowstreet Capital Limited Partnership | 1.31M | 2.24% | -5.03% | Jun 2026 |
| Two Sigma Investments LLC | 959K | 1.63% | +30.77% | Jun 2026 |
| AQR Capital Management LLC | 934K | 1.59% | +30.45% | Jun 2026 |
| SG Americas Securities, LLC | 883K | 1.50% | -56.26% | Jun 2026 |
| Valor Management LLC | 818K | 1.39% | +598.38% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 734K | 1.25% | -28.84% | Jun 2026 |
| UBS Group AG | 603K | 1.03% | +34.60% | Jun 2026 |
| DZ BANK AG Deutsche Zentral-Genossenschaftsbank Frankfurt am Main | 551K | 0.94% | -2.83% | Jun 2026 |
| Amvescap Plc. | 529K | 0.90% | -15.87% | Jun 2026 |
Harmony Biosciences Holdings company profile
- Company name
- Harmony Biosciences Holdings
- Ticker
- HRMY.US
- Exchange
- USA Stocks
- Listed since
- Aug 19, 2020
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 293
- Fiscal year end
- December
- Address
- 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
- Phone
- 484 539 9800
- Website
- harmonybiosciences.com
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings management
10- Mr. Jeffrey S. AroninFounder & Non-Executive Chairman · born 1968
- Dr. Jeffrey M. Dayno M.D.President, CEO & Director · born 1957
- Mr. Peter AnastasiouSenior Executive VP & COO · born 1970
- Dr. Kumar Budur M.D., M.S.Executive VP and Chief Medical & Scientific Officer · born 1971
- Mr. Andrew Serafin J.D., M.B.A.Executive VP & Chief Strategy Officer · born 1975
- Mr. Adam ZaeskeExecutive VP & Chief Commercial Officer · born 1973
- Mr. Stephen MollichellaSenior VP, Controller & Interim Principal Financial Officer
- Brennan DoyleVP & Head of Investor Relations
- Mr. Christian Ulrich J.D.Executive VP, General Counsel & Corporate Secretary
- Ms. Tricia GloverChief Compliance Officer